Questions around this news
What is the pilot study evaluating?
The release says the pilot study will evaluate an on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia, meaning inadequate blood flow and oxygen supply to tissue. It does not provide study methods or results; the announcement concerns the launch of an evaluation.
What is ischemia?
Ischemia occurs when a part of the body receives too little blood flow to meet its needs, limiting its oxygen supply. It can affect different organs. In the heart, reduced blood flow may be associated with coronary artery disease and can cause symptoms or tissue damage.
What does a 12-lead ECG record?
An electrocardiogram (ECG) records the heart’s electrical activity. A 12-lead ECG uses multiple views of that activity to help clinicians assess heart rhythm and identify patterns that may indicate cardiac problems. The word “lead” refers to a view of the heart’s electrical signals, not a separate wire for each view.
Which markets could the patch potentially affect?
The release says the patch has the potential to disrupt the long-term continuous monitor and mobile cardiac telemetry markets. It characterizes those markets together as a $2 billion opportunity. The announcement presents this as potential, not as evidence that the patch has entered either market or changed how those services are delivered.
- The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common.
- HeartBeam announced the launch of a pilot study focused on evaluating its on-demand 12-lead ECG patch in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia.
- The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam (NASDAQ: BEAT) has launched a new pilot study designed to evaluate its technology — a proprietary on-demand 12-lead ECG patch — in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- HeartBeam
- Ticker
- NASDAQ: BEAT
- Announcement
- Product
Key figures
- Long-term continuous monitor and mobile cardiac telemetry markets
- $2 billion
People
- Robert EnoCEO of HeartBeam
Products and programs
SEC filings
Earlier from HeartBeam
- HeartBeam (NASDAQ: BEAT) Study Shows Portable ECG Device Can Help Identify Heart Attack Risk
- HeartBeam (NASDAQ: BEAT) Advances Commercial Launch, Reports First-Quarter 2026 Results
- HeartBeam (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients
- HeartBeam (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates
- HeartBeam (NASDAQ: BEAT) Closes $10M Public Offering to Advance Cardiac Technology Commercialization
